Diligence memo · auto-generated · as of July 2, 2026
Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Diffusion Pharmaceuticals Inc. operates in Pharmaceuticals, based in CHARLOTTESVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Diffusion Pharmaceuticals Inc. has raised $140M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $86M on 2016-01-08.
Most recent recorded round closed around 2020-05-20.
Valuation (modeled)modeled
Provath models Diffusion Pharmaceuticals Inc. at approximately $26M (range $2.4M–$69M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.02× the median modeled value of Series C Pharmaceuticals companies in 2019–2021 (33 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 6.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 32% of those peers.
Closest niche peers: Verastem, Inc., Sentia Wellness, Inc., Oyster Point Pharma, Inc., Terns Pharmaceuticals, Inc., Theseus Pharmaceuticals, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.